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Section Editor: Andrzej BartkeBackground:Nutrient status of B vitamins, particularly folate and vitamin B-12,may be related to cognitive ageing
but epidemiological evidence remains inconclusive.
Objective: The aim of this study was to estimate the association of serum folate and vitamin B-12 concentrations
with cognitive function in middle-aged and older adults from three Central and Eastern European populations.
Methods:Men andwomen aged 45–69 at baseline participating in the Health, Alcohol and Psychosocial factors in
Eastern Europe (HAPIEE) study were recruited in Krakow (Poland), Kaunas (Lithuania) and six urban centres in
the Czech Republic. Tests of immediate and delayed recall, verbal ﬂuency and letter search were administered at
baseline and repeated in 2006–2008. Serum concentrations of biomarkers at baseline were measured in a sub-
sample of participants. Associations of vitaminquartileswith baseline (n=4166) and follow-up (n=2739) cog-
nitive domain-speciﬁc z-scores were estimated using multiple linear regression.
Results:After adjusting for confounders, folatewas positively associatedwith letter search and vitamin B-12with
word recall in cross-sectional analyses. In prospective analyses, participants in the highest quartile of folate had
higher verbal ﬂuency (p b 0.01) and immediate recall (p b 0.05) scores compared to those in the bottomquartile.
In addition, participants in the highest quartile of vitamin B-12 had signiﬁcantly higher verbal ﬂuency scores
(β= 0.12; 95% CI = 0.02, 0.21).
Conclusions: Folate and vitamin B-12 were positively associated with performance in some but not all cognitive
domains in older Central and Eastern Europeans. These ﬁndings do not lend unequivocal support to potential im-
portance of folate and vitamin B-12 status for cognitive function in older age. Long-term longitudinal studies and
randomised trials are required before drawing conclusions on the role of these vitamins in cognitive decline.







Maintaining cognitive function is a vital part of healthy ageing. With
population ageing, understanding the factorswhich contribute to cogni-
tive function and cognitive decline in older age has gained public health
importance. Nutritional factors have been identiﬁed as potentially im-
portant for cognitive function in later life (Beydoun et al., 2014;
Plassman et al., 2010). Folate and vitamin B-12 are among the nutrients
with potential signiﬁcance for retention of cognitive capabilities and
prevention of cognitive decline in old age.miology & Public Health, 1-19The roles of folate and vitamin B-12 in the central nervous system
function arewell-known and optimal status of these B-vitamins is likely
to be important for cognitive function across the life course. Folate is es-
sential for neural tube development in infancy, and both folate and vita-
min B-12 are involved in maintaining normal nervous system function
at all ages due to their crucial roles in the conversion of homocysteine
to methionine (Reynolds, 2006). Suboptimal dietary intakes and/or
age-related changes in absorption andmetabolism of folate and vitamin
B-12 can result in dysregulation of the homocysteine cycle and elevated
blood homocysteine levels (i.e. hyper-homocysteinaemia) which may
subsequently impair cognition either as an independent risk factor for
cardiovascular disease (Wald et al., 2002) or through direct neurotoxic
effects (Reynolds, 2006). (Reynolds, 2006). It is theoretically possible
that B vitamins affect cognitive ageing through mechanisms other
34 P. Horvat et al. / Experimental Gerontology 76 (2016) 33–38than homocysteine lowering. For example, the folate cycle involves syn-
thesis of methyl groups which are essential for a number of genomic
and non-genomic methylation reactions (Reynolds, 2006), including
the synthesis of S-adenosylmethionine, themethyl donor for the central
nervous system (Morris, 2012), as well as methyl groups used in syn-
thesis of DNA nucleotides. The latter, in particular, could stimulate
adult neurogenesis in the hippocampuswhich is important formemory,
sensitive to ageing-related changes (Morris, 2012) and one of the ﬁrst
regions of the brain to show signs of atrophy in Alzheimer's disease. Fi-
nally, low vitamin B 12 status may increase cardiovascular risk partly
through direct effects, and not exclusively through hyperhomocysteine-
mia, with potential consequences for cognition; however, the evidence
supporting this hypothesis is limited (Rafnsson et al., 2011).
The epidemiological evidence on the associations of blood folate and
vitamin B-12 with cognitive ageing remains inconclusive. Numerous
studies have reported cross-sectional associations between blood folate
and vitamin B-12 and cognitive function (de Lau et al., 2007; Duthie
et al., 2002; Elias et al., 2006; Feng et al., 2006; Kado et al., 2005;
Ramos et al., 2005; Tucker et al., 2005), although the evidence seems
stronger for folate than for vitamin B 12. Evidence from prospective
studies is less consistent. Signiﬁcant associations between low blood fo-
late and vitamin B-12 and poorer cognition or accelerated cognitive de-
cline have also been reported by some (Clarke et al., 2007; Feng et al.,
2006; Morris, 2012; Tangney et al., 2009) but not all (de Lau et al.,
2009; Kang et al., 2006; Langa et al., 2008; Mooijaart et al., 2005) longi-
tudinal studies.
The homocysteine hypothesis of cardiovascular disease suggests
that cognitive domains which are sensitive to vascular risk factors are
also vulnerable to low folate and vitamin B 12 status. Folate, vitamin B
12 andhomocysteinemay also be differentially related to speciﬁc cogni-
tive domains; elevated homocysteine has been linked to slower pro-
cessing speed, low folate to impaired memory function, and low
vitamin B-12 to both slower processing speed and worse memory per-
formance but only in studies using sensitive markers of vitamin B 12,
such as methylmalonic acid and holotranscobalmin (Morris, 2012). De-
spite some evidence linking folate and vitamin B-12 to speciﬁc cognitive
domains, the inconsistency of associations in terms of cognitive tests
and domains within and across studies (Doets et al., 2013) makes it dif-
ﬁcult to draw ﬁrm conclusions about domain-speciﬁc associations and
the differential contributions, if any, of these B vitamins.
The aim of this study is to examine cross-sectional and prospective
associations between serum biomarkers of folate and vitamin B-12 and
cognitive function inmiddle and older age usingwell-characterised sam-
ples from three Central and Eastern European populations.
2. Methods
2.1. Study populations and participants
The HAPIEE (Health, Alcohol and Psychosocial factors In Eastern
Europe) study protocol has been described in detail elsewhere (Peasey
et al., 2006). Brieﬂy, random samples of 36,106 men and women aged
45–69 years at baseline were recruited in Novosibirsk (Russia), Krakow
(Poland), Kaunas (Lithuania) and six middle-sized urban centres in the
CzechRepublic using population registers. The baseline surveywas con-
ducted in 2002–2005 in the Czech Republic, Krakow and Novosibirsk,
and in 2006–2008 in Kaunas which joined the study later. Average re-
sponse rate was 61%. The baseline survey consisted of an extensive
health questionnaire and a brief physical examination, including a ve-
nous blood sample. Czech and Krakow participants completed the sur-
vey questionnaire during a nurse visit to their home and were
subsequently invited to attend a medical examination in a clinic. Novo-
sibirsk and Kaunas participants completed both the questionnaire and
the medical examination during a clinic visit. In 2006–2008, Czech,
KrakowandNovosibirsk participantswere re-interviewedwith an aver-
age response rate of 63%. In 2002–2005, all participants older than60 years and a random sample of approximately 20% of younger partic-
ipants in the Czech Republic, Krakow andNovosibirsk underwent a cog-
nitive assessment. In Krakow, cognitive assessment was conducted in
participants' homes; in all other centres it was conducted as part of
the clinic visit. In 2006–2008, cognitive assessment was completed for
all Kaunas participants and all returning participants in the remaining
three centres (n = 17,543); for 54% (n = 9436) of returning partici-
pants this was their ﬁrst assessment of cognitive function.
Fasting venous blood samples were collected during the clinic visits
in all centres, following standardized protocols for collection and stor-
age of samples. Due to legal restrictions on exporting blood samples
from Russia (n = 9360), biomarkers were measured only in the
Czech, Krakow and Kaunas samples (n = 26,746). Biomarkers were
analysed in a nested case–control sub-study. The selection of partici-
pants in the nested case–control study was as follows: of 26,746 partic-
ipants, 3462 were excluded because blood samples were unavailable,
another 1867 participantswithdrew from follow-up, 208 had an uncon-
ﬁrmed cardiovascular event and 3324 had a previous history of cardio-
vascular disease. Among the 17,885 remaining participants, there were
1882 cases (those who died from any cause or experienced a non-fatal
cardiovascular event during follow-up) and 16,003 potential controls.
Biomarkers were measured in the 1882 cases and 4476 randomly-
selected controls frequency matched to cases by cohort, sex and age
group.
The study was approved by ethics committees at University College
London and University College Hospital and local ethics committees in




Cognitive function was assessed by four neuropsychological tests
(Horvat et al., 2015): i.) immediate word recall (10 nouns over three
consecutive 1 min trials); ii.) delayed recall (10 nouns following an in-
terval), both used as tests of verbal memory and learning; iii.) category
verbal ﬂuency (animal naming) used as a measure of language and
executive function; and iv.) timed letter search used to assess concen-
tration, mental speed and accuracy. Given the previously observed
domain-speciﬁc associations (Morris, 2012), we might expect both fo-
late and vitamin B 12 to be associatedwith tests ofmemory,whereas vi-
tamin B 12 statusmay also be associatedwith performance on the timed
letter search task. Associations of folate and vitamin B 12 status with
category ﬂuency performance have also been reported by some studies
(Feng et al., 2006; Hooshmand et al., 2012).
2.2.2. Folate and vitamin B-12
Fasting blood samples were collected in Becton Dickinson SST II
(10 ml) and K2-EDTA vacutainers (10 ml and 2 × 3 ml). All vacutainers
were stored at 4 degrees Celsius prior to processing. The 10 ml SST II
and 10 ml K2-EDTA vacutainers were centrifuged at 4000 rpm for
15 min, and serum and plasma samples were each divided into several
aliquots. All aliquots were stored in 1.5 ml Sarstedt microtubes at
−80 °C for subsequent laboratory analysis. Folate and vitamin B12
were determined in serum with a homogenous chemiluminescent im-
munoassay using the Access-2 immuno-analyser of Beckman-Coulter,
Woerden, the Netherlands. Folate concentrations were expressed in
ng/ml, over a detectable range of 0.5 to 20.0. Vitamin B-12 concentra-
tions were expressed in pmol/l, over a detectable range of 37 to 1100.
The inter-assay variation was 4.4% for folate and 5.7% for vitamin B-12.
2.2.3. Covariates
In order to minimize potential confounding, covariates were select-
ed based on existing literature (7), hypothesised relationships with the
outcomes, and associations with exposures or outcomes in the current
cohorts. The following potential confounders were included in the
35P. Horvat et al. / Experimental Gerontology 76 (2016) 33–38statistical analyses: age at cognitive assessment, sex, study centre, edu-
cation (primary or less, more than primary but less than tertiary, and
tertiary), current economic activity (employed, self-employed, working
pensioner, non-working pensioner, unemployed, and other (e.g. house-
wife, disabled)), smoking status (never, current, former), average alco-
hol use in last 12 months (0 g/day, b5/10 g/day, 5–20/10–50 g/day,
and N20/50 g/day in women and men, respectively), and case–control
status.We also adjusted for potential mediators: coronary heart disease,
stroke, hypertension, and diabetes (all self-reported and dichotomous;
yes vs. no).Table 1













Folate (ng/ml) 8.7 (4.0) 8.7 (4.0)
Vitamin B-12 (pmol/l) 243.8 (115.1) 246.7 (112.1)
Age 64.5 (5.4) 65.3 (6.4)
Immediate recall 20.5 (4.1) 21.4 (4.1)
Delayed recall 7.1 (1.9) 7.1 (1.9)
Verbal ﬂuency 20.8 (6.4) 22.5 (6.4)
Letter search 16.3 (5.2) 17.3 (4.7)
Center
Czech towns 1355 32.5 1403 51.2
Krakow (Poland) 1163 27.9 1336 48.8
Kaunas (Lithuania) 1648 39.6 NA NA
Sex
Male 2768 66.4 1844 67.3
Education
Primary or less 498 12.0 244 8.9
Secondary 2314 55.5 1804 65.9
College or university 1354 32.5 691 25.2
Current economic activity
Full-time/part-time employed 609 14.6 605 22.1
Self-employed 87 2.1 138 5.0
Pensionable age, still working 641 15.4 300 11.0
Pensionable age, not working 2689 64.5 1607 58.7
Unemployed 54 1.3 57 2.1
Other 86 2.1 32 1.2
Smoking status
Never smoker 1932 46.4 1111 40.6
Former smoker 1295 31.1 934 34.1
Current smoker 939 22.5 694 25.3
Self-reported history of
Myocardial infarction 461 11.1 227 8.3
Stroke 176 4.2 81 3.0
Hypertension 2520 60.5 1485 54.2
Diabetes 591 14.2 381 13.9
Alcohol intake (g/day)
0 722 17.3 539 19.7
b5/10 2473 59.4 1512 55.2
5–20/10–50 819 19.7 535 19.5
N20/50 152 3.6 153 5.6
Case–control status
Case 1195 28.7 475 17.3
Control 2971 71.3 2264 82.72.3. Statistical analysis
We estimated cross-sectional and prospective associations between
B-vitamin biomarkers and cognitive function using four cognitive mea-
sures from two study waves (baseline and re-examination) as out-
comes and serum folate and vitamin B-12 measured at baseline as the
main exposure variables. Participants were eligible for inclusion in the
present analysis if they had biomarker measurements at baseline and
at least one cognitive function measurement (from baseline and/or re-
examination). In cross-sectional analyses, only variables measured at
baselinewere used; in prospective analyses, we used cognitive function
from re-examination and biomarkers and covariates frombaseline. Pro-
spective analyses were restricted to participants from Czech towns and
Krakow, as only the baseline survey was available in Kaunas. For pro-
spective analysis, follow-up timewas deﬁned as the timebetweenmea-
surement of vitamin biomarkers in serum at baseline (2002–05) and
measurement of cognitive performance at re-examination (2006–
2008).
All cognitive outcomes were converted to z-scores (mean = 0;
sd = 1) using the full study sample means and standard deviations
to allow comparison between tests (Horvat et al., 2015). Biomarkers
were categorized into quartiles (see Table A.1 for cut-off values). For
each cognitive test, separate multiple linear regression models were
ﬁtted for quartiles of each biomarker. In the test for trend analysis,
wemodelled the biomarker quartiles as continuous. Additionally, re-
gression models for each cognitive outcomewere re-ﬁtted using log-
transformed folate or vitamin B-12 concentrations as independent
variable. The regression models were initially adjusted only for age
and sex, and then additionally adjusted for the remaining con-
founders and, ﬁnally, for potential mediators. All models were ad-
justed for cohort and case–control status. Models using cognitive
measures from re-examination as outcomes were also adjusted for
cognitive testing occasion (ﬁrst test vs. re-test) in order to control
for potential confounding by learning effects from repeated test tak-
ing. Analyses were conducted in participants with complete data on
all model variables. We also tested for possible interactions of bio-
markers with sex, age, cohort and alcohol intake.
A number of sensitivity analyses were conducted to examine
whether the potential associations were mainly due to biomarkers
and/or cognitive outcomes acting as indicators of underlying disease
or ill-health and to check the overall robustness of the conclusions.
First, we repeated the analysis using only controls because overrep-
resentation of cases who were generally less healthy and more likely
to die or drop-out before re-examination in the nested case–control
design could have affected the generalizability of our ﬁndings. We
also re-estimated the regression models after excluding: 1.) partici-
pants who died within 2 years of the baseline survey, 2.) participants
with biomarker values at the extremes of the distribution (below 5th
or above 95th percentile), 3.) participants who experienced a fatal or
non-fatal coronary event or stroke during follow-up, and 4.) partici-
pants with prevalent coronary heart disease, stroke or diabetes. Fi-
nally, we also re-estimated the regression models after additionally
controlling for follow-up time. Analyses were conducted in Stata 13
(StataCorp, 2011).3. Results
Descriptive characteristics of the study sample are shown in Table 1
(and by case–control status in Table A.2). Biomarker and cognitive func-
tion data were available for 4512 participants for cross-sectional and
3044 participants for prospective analysis. After excluding observations
with any missing values from the analysis, the numbers of participants
with complete data were 4166 in cross-sectional and 2739 in prospec-
tive analyses. For prospective analysis, mean follow-up time was
3.8 ± 0.4 years (range 1.8–5.5 years). Of the 2739 participants in pro-
spective analysis, 1702 had repeated cognitive measures, and had a
mean age of 64.7 years at baseline and 68.4 years at re-examination.
Mean age of participants for prospective sample as a whole was
65.3 years, and 64.5 years for the cross-sectional sample. Over 66% of
the samples were from men; because of higher male cardiovascular
and total mortality men were overrepresented in the nested case–con-
trol study. Average baseline values were 8.7 ng/ml (±4.0) for folate and
243.8 pmol/l (±115.1) for vitamin B-12.
Results of fully-adjusted multiple regression analyses for folate and
cognitive performance are shown in Table 2. In cross-sectional analysis,
Table 2









b 95% CI b 95% CI b 95% CI b 95% CI
Cross-sectional (n = 4166)a
Folate (ng/ml)
1st quartile 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00]
2nd quartile 0.03 [−0.05, 0.10] 0.05 [−0.03, 0.13] 0.02 [−0.05, 0.09] 0.03 [−0.05, 0.11]
3rd quartile 0.05 [−0.03, 0.12] 0.05 [−0.03, 0.13] 0.07⁎ [0.00, 0.15] 0.11⁎⁎ [0.03, 0.20]
4th quartile 0.06 [−0.01, 0.14] 0.04 [−0.04, 0.12] 0.05 [−0.02, 0.13] 0.10⁎ [0.01, 0.18]
p for trend 0.083 0.362 0.070 0.008
p for logged folatec 0.111 0.055 0.132 0.007
Prospective (n = 2739)b
Folate (ng/ml)
1st quartile 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00]
2nd quartile 0.05 [−0.04, 0.15] 0.01 [−0.09, 0.11] 0.05 [−0.04, 0.14] 0.01 [−0.09, 0.11]
3rd quartile 0.06 [−0.03, 0.16] −0.01 [−0.11, 0.08] 0.09 [−0.01, 0.18] −0.01 [−0.10, 0.09]
4th quartile 0.10⁎ [0.00, 0.20] 0.02 [−0.08, 0.12] 0.13⁎⁎ [0.03, 0.22] 0.07 [−0.03, 0.16]
p for trend 0.050 0.839 0.006 0.251
p for logged folate 0.077 0.306 0.031 0.207
⁎ p ≤ 0.05.
⁎⁎ p ≤ 0.01.
a Cross-sectional models were adjusted for age, sex, study centre, education, current economic activity, smoking, alcohol, self-reported history of chronic conditions and case–control status.
b Prospective models were additionally adjusted for cognitive testing occasion.
c p-Value associated with log-transformed biomarker used as independent variable in regression analysis.
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better letter search performance. The associated p-value for trend indi-
cated statistical signiﬁcance (p b 0.01), as did the p-value (p b 0.01)
from analysis with log-transformed folate as the independent variable.
Additionally, participants in the third quartile of serum folate had higher
verbalﬂuency scores compared to participants in the bottomquartile. In
prospective models, high folate concentrations were also signiﬁcantly
associated with better performance on verbal ﬂuency, and the associat-
ed p-value for linear trend (p-value b 0.01) and log-transformed results
(p-value = 0.03) were statistically signiﬁcant. In prospective analysis,
the difference between top and bottom quartiles of folate also reached
statistical signiﬁcance for immediate recall but not for letter search. De-
layed recall was not associated with serum folate levels in any of the
analyses.
Fully-adjusted regression results for vitamin B-12 and cognition are
shown in Table 3. Participants in the top quartile of serum vitamin B-
12 had signiﬁcantly better scores on both immediate and delayed recall
tests in cross-sectional models, and the associated p-values for trend
were signiﬁcant. These associations were not replicated in prospective
models; differences inmemory scores between top and bottom quartiles
of serum vitamin B-12were not signiﬁcant. However, high levels of vita-
min B-12 were prospectively associated with better verbal ﬂuency rela-
tive to being in the lowest quartile of the biomarker. The associated test
for trend and the p-value for the association with log-transformed vita-
min B-12 were also signiﬁcant. The association between serum vitamin
B-12 concentrations and letter search was not in the expected direction,
although, with the exception of second quartile in cross-sectional analy-
sis, it was not statistically signiﬁcant.
There were few statistically signiﬁcant interactions, mostly at 5%
level of signiﬁcance, between biomarkers and age, sex, cohort or alcohol
intake in the associationwith cognitive test performance. It is likely that
some borderline signiﬁcant interactions resulted from multiple testing.
Results of sensitivity analysis suggested that the observed associations,
or lack thereof, between both vitamin biomarkers and cognitive out-
comeswere generally robust (reported in Tables A.3–A.7). After exclud-
ing cases from the analysis, cross-sectional and prospective associations
between the vitamins and verbal ﬂuency were slightly strengthened
(Table A.3). However, after excluding participantswith pre-existing car-
diovascular disease and diabetes from the analysis, the associationsbetween the vitamins and verbal ﬂuency were slightly attenuated
(Table A.7).
4. Discussion
This study found evidence of positive associations between folate
and vitamin B-12 concentrations and performance in some but not all
cognitive domains in a cohort of middle-aged and older Central and
Eastern Europeans. Folate was positively associated with verbal ﬂuency
and borderline associated with immediate recall in prospective analy-
ses. Furthermore, higher concentrations of folate were associated with
better letter search performance in cross-sectional analysis. Associa-
tions between vitamin B-12 and memory, observed cross-sectionally,
were not detected in prospective analysis but high levels of vitamin B-
12were prospectively associatedwith better verbal ﬂuency. This associ-
ation followed a signiﬁcant linear trend.
The results of our study should be interpreted in the context of its
limitations. First, the analytic sample was restricted to participants
with complete data. Although biomarkers were only measured in a
case–control subsample, inclusion of the variables used in the selection
of the case–control subsample (sex, age, cohort and case–control status)
as covariates in the regression models is considered to result in unbi-
ased estimates using complete case analysis in absence of inverse prob-
ability weighting. However, missing data on covariates and cognitive
function could still have affected our results, in particular longitudinal
attrition in prospective analyses.
Second, response rates were relatively low, although this is typical
for most contemporary epidemiologic studies (Galea and Tracy, 2007).
As responders tended to be healthier than non-responders (Peasey
et al., 2006), participation rates may have been lower in those with
poor cognition and unfavourable vitamin proﬁles. Because of this, it is
possible that the absolute levels of cognitive performance and bio-
markers were overestimated in our study. However, nonresponse
rates are not a good predictor of nonresponse bias (Groves, 2006), and
effect estimates of associations between vitamin biomarkers and cogni-
tive function may be relatively unbiased.
Third, we did not have direct information on dietary supplementa-
tion of folate and vitamin B-12. It is possible that thosewho take dietary
supplements have healthier behaviours which may positively impact
Table 3









b 95% CI b 95% CI b 95% CI b 95% CI
Cross-sectional (n = 4166)a
Vitamin B-12 (pmol/l)
1st quartile 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00]
2nd quartile 0.04 [−0.04, 0.11] 0.06 [−0.01, 0.14] −0.02 [−0.09, 0.05] −0.09⁎ [−0.18,-0.01]
3rd quartile 0.05 [−0.02, 0.13] 0.05 [−0.03, 0.13] −0.00 [−0.07, 0.07] −0.06 [−0.14, 0.03]
4th quartile 0.09⁎ [0.02, 0.17] 0.09⁎ [0.01, 0.17] 0.05 [−0.02, 0.12] −0.08 [−0.17, 0.00]
p for trend 0.016 0.038 0.137 0.115
p for logged vitamin B-12c 0.007 0.022 0.106 0.048
Prospective (n = 2739)b
Vitamin B-12 (pmol/l)
1st quartile 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00]
2nd quartile 0.00 [−0.09, 0.10] −0.00 [−0.10, 0.10] 0.01 [−0.08, 0.10] −0.02 [−0.12, 0.07]
3rd quartile 0.08 [−0.02, 0.17] 0.08 [−0.02, 0.18] 0.06 [−0.03, 0.16] 0.06 [−0.04, 0.15]
4th quartile 0.06 [−0.04, 0.16] 0.04 [−0.06, 0.14] 0.12⁎ [0.02, 0.21] −0.00 [−0.10, 0.10]
p for trend 0.098 0.190 0.007 0.590
p for logged vitamin B-12 0.043 0.203 0.024 0.798
⁎ p ≤ 0.05.
⁎⁎ p ≤ 0.01.
a Cross-sectional models were adjusted for age, sex, study centre, education, current economic activity, smoking, alcohol, self-reported history of chronic conditions and case–control
status.
b Prospective models were additionally adjusted for cognitive testing occasion.
c p-Value associated with log-transformed biomarker used as independent variable in regression analysis.
37P. Horvat et al. / Experimental Gerontology 76 (2016) 33–38cognitive performance. However, the prevalence of any vitamin supple-
mentation is low in the HAPIEE cohorts, with no clear inverse
association between antioxidant vitamin intake and subsequentmortal-
ity (Stepaniak et al., 2015). In addition, our analytical models were ad-
justed for the main health behaviours, including smoking and alcohol
consumption.
While not a direct limitation,we have notmeasured blood homocys-
teine and could not explore its association with folate and vitamin B-12
status in the relationship with cognitive function. It would also be inter-
esting to compare mean values for serum folate and vitamin B 12 status
and mean cognitive performance in Central and Eastern European co-
horts with other European or international cohorts. However, method-
ological differences in measurement of biomarkers and cognition
between our study and previous studies (Bobak et al., 2009) make
such direct comparisons difﬁcult.
Strengths of this study include objective assessments of vitamin bio-
markers and cognitive function, and relatively large well-characterised
samples from three Central and Eastern European populations.
In our study, folatewas positively associatedwith verbal ﬂuency.We
also observed aweakly signiﬁcant prospective association between high
folate levels and better immediate recall, and better performance on the
letter search task, assessing mental speed, in cross-sectional analysis.
Most cross-sectional studies of blood folate and performance on neuro-
psychological tests found a signiﬁcant association with at least one test,
although studies of memory were almost as likely to ﬁnd no association
as a signiﬁcant association (Morris, 2012). However, cross-sectional
studies cannot establish a temporal relationship between the exposure
and the outcome.
Our observation that folate was prospectively associatedwith verbal
ﬂuency (and weakly associated with working memory) over a 3-year
follow-up period, raises the possibility of a causal association, at least
in some cognitive domains. A previous longitudinal study linked high
serum folate to slower decline in spatial copying ability and high dietary
folate with improved verbal ﬂuency over a 3-year follow-up period
(Tucker et al., 2005). In another prospective study, low folate status
was linked to accelerated 7-year decline in global cognition (Kado
et al., 2005). However, not all prospective studies have observed an as-
sociation (Clarke et al., 2007; Kang et al., 2006). Results from
randomised trials have been similar. Folic acid supplementation wasassociated with improved domain-speciﬁc cognitive performance in
two (Durga et al., 2007;Walker et al., 2012) of the three randomised tri-
als with relatively large samples and two or more years of follow-up
(Durga et al., 2007; McMahon et al., 2006; Walker et al., 2012).
We observed cross-sectional but not prospective associations be-
tween vitamin B-12 and memory. Vitamin B-12 was prospectively asso-
ciated with better verbal ﬂuency, and the association followed a linear
trend. Our results do not suggest a particularly strong relationship be-
tween vitamin B-12 and cognitive performance in middle and older
age. This is broadly in line with a recent systematic review and meta-
analysis of prospective studies which did not ﬁnd consistent evidence
for the hypothesis relating vitamin B-12 status to global or domain-
speciﬁc cognitive performance in older people (Doets et al., 2013). Sim-
ilar to our study, some prospective cohort studies have reported positive
domain-speciﬁc ﬁndings, particularly between vitamin B-12 and execu-
tive function or memory, but the results have been inconsistent across
studies (Doets et al., 2013). In a recent randomised trial, vitamin B-12
supplementation was not associated with improved cognitive and neu-
rological functions after 12months in 201 participantswithmild vitamin
B-12 deﬁciency (Dangour et al., 2015). These ﬁndings do not support the
hypothesis that optimizing vitamin B-12 status beneﬁts cognitive func-
tion in older age, although with a mean age of 80 years the results of
this trial are not directly comparable to our study population.
It is also possible that serum vitamin B-12 is not sensitive enough to
detect associations with cognitive ageing. Other markers, such as
methylmalonic acid and holotranscobalamin, are thought to be more
sensitive but are not yet routinelymeasured in population studies. Stud-
ies which used thesemarkers weremore likely to observe positive asso-
ciations between low vitamin B-12 concentrations and increased
cognitive risk but such studies are currently few in number (Clarke
et al., 2007; Doets and others; Morris, 2012; O'Leary et al., 2012).
There is no universally agreedmeasurement standard for determina-
tion of folate and vitamin B-12 status, and the interpretation of lower
values in not always clear. In addition, variation in blood folate and vita-
min B-12 levels within the currently considered normal range may also
be signiﬁcant for cognitive function. We explored a dose–response rela-
tionship between folate and vitamin B-12 and cognitive performance,
and found evidence for a signiﬁcant linear trend in prospective associa-
tions of both folate and vitamin B-12 with verbal ﬂuency, as well as
38 P. Horvat et al. / Experimental Gerontology 76 (2016) 33–38cross-sectional associations between folate and timed letter search and
vitamin B-12 and memory.
5. Conclusions
Folate and, to a lesser extent, vitamin B-12 were positively associat-
edwith performance in some cognitive domains in our study inmiddle-
aged and older Central and Eastern Europeans. Both folate and vitamin
B-12 were prospectively associated with verbal ﬂuency over a 3-year
follow-up period. Since prospective associations are less likely to be af-
fected by reverse causation, this ﬁnding is, at least, suggestive of a pos-
sible association in speciﬁc cognitive domains. However, neither
vitamin showed consistent relationships both cross-sectionally and pro-
spectively or across cognitive tests. Longitudinal studies with longer
follow-ups, high-quality randomised trials and genetic studies are need-
ed before drawing ﬁrm conclusions on the causal role of folate and vita-
min B-12 in cognitive ageing and potential preventative or therapeutic
beneﬁts for cognition of optimizing folate and vitamin B-12 status in
older people.
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